Mirati Therapeutics | MRTX - Заемный капитал



Заемный капитал Изменить Дата
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
Astellas Pharma JPY 320B 0 2025-12
AstraZeneca USD 26.14B 19.58B 2025-12
Bayer EUR 31.83B 877M 2025-12
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Eisai JPY 134.77B 12M 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Gilead Sciences USD 22.14B 5M 2025-09
GlaxoSmithKline GBP 14.71B 186M 2025-12
Incyte USD 30.2M 5.17M 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
J&J USD 39.44B 30M 2025-12
Merck USD 39.97B 6B 2025-09
Moderna USD 610M 584M 2025-12
Nektar Therapeutics USD 107.51M 10.35M 2024-06
Novartis USD 24.24B 174M 2025-09
Pfizer USD 57.41B 93M 2025-09
Puma Biotechnology USD 10.87M 222K 2025-06
Roche Holding CHF 27.43B 966M 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Takeda JPY 4.27T 81.29B 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09